Get startedLog in
    Picture of Kintor Pharmaceutical logo

    9939 — Kintor Pharmaceutical News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapSucker Stock
    All News

    Brief: Kintor Pharmaceutical Updates On Prelim Results From Clinical Trial Of Proxalutamide For Treatment Of Covid-19

    Picture of Kintor Pharmaceutical logoKintor Pharmaceutical
    11/12/2020 11:11
    Dec 11 (Reuters) - Kintor Pharmaceutical Ltd  9939.HK :
    * UPDATES ON PRELIMINARY RESULTS FROM CLINICAL TRIAL OF-
PROXALUTAMIDE FOR TREATMENT OF COVID-19
    * PROXALUTAMIDE COULD LIMIT EXPRESSION OF ACE-2 & TMPRSS2
    * ACE-2 & TMPRSS2 PLAY CRITICAL ROLE FOR SARS-COV-2 TO BIND
&
ENTER HOST CELLS IN LUNG
    * ACTIVELY PREPARING FOR MULTI-REGIONAL CLINICAL TRIALS IN
CHINA &
U.S.

Source text for Eikon:  urn:newsml:reuters.com:*:nHKS9T2kpC
Further company coverage:  9939.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Kintor Pharmaceutical

    See all news